Effects of different omeprazole dosing on gastric pH in non‐variceal upper gastrointestinal bleeding: A randomized prospective study

We aimed to identify the best method of omeprazole (OME) application with respect to intragastric pH, cytochrome P450 2C19 (CYP2C19) genotype and phenotype.

[1]  L. Laine,et al.  Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. , 2014, JAMA internal medicine.

[2]  Justin C.Y. Wu,et al.  Effects of Intravenous and Oral Esomeprazole in the Prevention of Recurrent Bleeding from Peptic Ulcers after Endoscopic Therapy , 2012, The American Journal of Gastroenterology.

[3]  J. West,et al.  Comorbidities Affect Risk of Nonvariceal Upper Gastrointestinal Bleeding , 2013, Gastroenterology.

[4]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapeutics.

[5]  Nayoung Kim,et al.  Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors , 2013, Journal of neurogastroenterology and motility.

[6]  K. Sangkuhl,et al.  Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013 .

[7]  S. Kopic,et al.  Gastric acid, calcium absorption, and their impact on bone health. , 2013, Physiological reviews.

[8]  S. Chuah,et al.  A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding , 2012, Gastroenterology research and practice.

[9]  H. Yen,et al.  Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy , 2012, BMC Gastroenterology.

[10]  Jian Liu,et al.  Relative bioavailability and pharmacokinetic comparison of two different enteric formulations of omeprazole , 2012, Journal of Zhejiang University SCIENCE B.

[11]  Ming‐Luen Hu,et al.  Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis , 2012, BMC Gastroenterology.

[12]  D. Flockhart,et al.  Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers , 2012, Clinical pharmacology and therapeutics.

[13]  Loren Laine,et al.  Management of Patients With Ulcer Bleeding , 2012, The American Journal of Gastroenterology.

[14]  F. Gao,et al.  High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis. , 2010, World journal of gastroenterology.

[15]  R. Hunt,et al.  International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding , 2010, Annals of Internal Medicine.

[16]  G. M. Gulzar,et al.  Comparison of p.o. or i.v. proton pump inhibitors on 72‐h intragastric pH in bleeding peptic ulcer , 2009, Journal of gastroenterology and hepatology.

[17]  L. Laine,et al.  Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. , 2008, Gastroenterology.

[18]  M. Ingelman-Sundberg,et al.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. , 2008, British journal of clinical pharmacology.

[19]  M. Hayakari,et al.  Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration , 2007, European Journal of Clinical Pharmacology.

[20]  B. Hunt,et al.  Lansoprazole regimens that sustain intragastric pH >6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages , 2006, Alimentary pharmacology & therapeutics.

[21]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[22]  A. Chow,et al.  Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability , 2004, Journal of clinical pharmacology.

[23]  D. Castell,et al.  Proton pump inhibitors: better acid suppression when taken before a meal than without a meal , 2000, Alimentary pharmacology & therapeutics.

[24]  A. Blum,et al.  The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection , 2000, American Journal of Gastroenterology.

[25]  S. Higuchi,et al.  Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. , 1999, British journal of clinical pharmacology.

[26]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.